TABLE 3.
Univariate and multivariate analysis of PFS of osimertinib plus anlotinib in the treatment
| Variate | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| Age | 1.427 (0.640–3.182) | 0.385 | ||
| Sex | 1.512 (0.683–3.346) | 0.307 | ||
| Smoking history | 0.667 (0.199–2.238) | 0.513 | ||
| ECOG PS | 6.767 (2.060–22.237) | 0.002* | 7.207 (2.110–24.619) | 0.002 |
| EGFR genotype | 1.144 (0.781–1.676) | 0.489 | ||
| Family history | 0.997 (0.401–2.480) | 0.995 | ||
| Primary disease | 0.912 (0.416–1.998) | 0.818 | ||
| Prior chemotherapy | 1.375 (0.551–3.434) | 0.495 | ||
| Prior bevacizumab | 0.959 (0.383–2.384) | 0.923 | ||
| Prior radiotherapy | 0.350 (0.120–1.020) | 0.054 | ||
| Prior operation | 0.842 (0.377–1.880) | 0.674 | ||
| Brain metastases | 2.182 (0.981–4.851) | 0.056 | ||
| Bone metastases | 2.467 (1.040–5.851) | 0.040* | 2.541 (1.061–6.083) | 0.036 |
| Liver metastases | 2.467 (0.726–8.383) | 0.148 | ||
| Pleural metastases | 0.653 (0.247–1.729) | 0.391 | ||
| Malignant pleural effusion | 2.303 (0.895–5.928) | 0.084 | ||
Abbreviations: CI, confidence interval; ECOG PS, eastern cooperative oncology group performance status; EGFR, epidermal growth factor receptor; HR, hazard ratio.
*
p < 0.05.